Quick Answer
HCW Biologics Inc. reported Cash And Cash Equivalents At Carrying Value of $1.95 million for the year ending 2025.
- HCW Biologics Inc. showed a decrease of -58.2% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from HCW Biologics Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $3.17 million | Q3 2020: $6.48 million | Q2 2021: $5.05 million | Q3 2021: $15.13 million | Q1 2022: $18.12 million | Q2 2022: $15.42 million | Q3 2022: $26.22 million | Q1 2023: $18.39 million | Q2 2023: $7.45 million | Q3 2023: $11.22 million | Q1 2024: $4.08 million | Q2 2024: $1.16 million | Q3 2024: $998.2 thousand | Q1 2025: $1.11 million | Q2 2025: $2.44 million | Q3 2025: $1.10 million.
- Over the full 7 years of available data (2019 to 2025), HCW Biologics Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 73.5%.
- Historical annual values: Fiscal year 2025: $1.95 million | Fiscal year 2024: $4.67 million | Fiscal year 2023: $3.60 million | Fiscal year 2022: $22.33 million | Fiscal year 2021: $11.73 million | Fiscal year 2020: $8.46 million | Fiscal year 2019: $7.36 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: